Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly period ended October 31, 1997 (Three and Six Months).
Status: Development Stage Enterprise in pre-clinical trial phase.
Going Concern: Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated losses of $8.88 million and a working capital deficit of $567,109. Continuation depends on obtaining additional financing and FDA approval.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 1997 | Six Months Ended Oct 31, 1997 | Accumulated (Development Stage) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(377,517) | $(594,588) | $(8,881,720) |
| Net Loss Per Share | $(0.01) | $(0.01) | $(0.01) |
| Cash and Equivalents | $99,619 (Ending Balance) | $99,619 (Ending Balance) | N/A |
| Working Capital | $(567,109) Deficit | $(567,109) Deficit | N/A |
| Total Liabilities | $676,373 | $676,373 | N/A |
| Stockholders' Equity | $(343,100) | $(343,100) | $(343,100) |
Expense Breakdown (Six Months 1997): Research & Development ($83,533); General & Administrative ($508,659); Interest ($3,289).
Material Changes vs. Prior Period
- Expense Reduction: Significant decrease in expenses compared to the prior year. R&D expenses dropped from $149,071 to $83,533 (six months), and G&A dropped from $724,946 to $508,659. Management attributes this to reduced research personnel, fewer animal purchases, and lower legal/licensing fees.
- Net Loss Improvement: Net loss for the six months ended Oct 31, 1997, was $594,588, a reduction from $1,013,053 in the prior year period.
- Capital Structure: Issued 2,000,000 shares to Argos Invest Consult AG for $260,000 and 1,044,450 shares to officers/directors to cancel $94,000 in loans. Also issued convertible debentures for $31,000.
- Cash Flow: Net cash used in operating activities was $594,588 for the six months ended Oct 31, 1997, compared to $1,013,053 in the prior year. Financing activities provided $602,444 in net cash.
Outlook, Risks, and Contingencies
- Outlook: The company is actively pursuing strategic alliances and joint ventures to fund Phase I, II, and III human testing. No assurance is given that funding will be obtained or FDA approval granted.
- Litigation: Two pending legal matters filed by former employees regarding a 1995 layoff. Management estimates exposure at $124,000, which has been accrued.
- Commitments: Employment agreements with future commitments of $240,000 in 1998.
- Accounting Changes: The company will adopt FAS 128 (Earnings Per Share) for the fiscal year ending April 30, 1998, though it expects no material difference in reported EPS.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to secure the significant additional financing required for clinical trials given the $567,109 working capital deficit.
- Going Concern Status: Assess the risk of insolvency if future private placements or joint ventures are not secured.
- Litigation Exposure: Confirm the status of the $124,000 accrued liability related to former employee lawsuits.
- Regulatory Path: Evaluate the timeline and probability of FDA approval for pre-clinical products.
- Dilution Risk: Review recent stock issuances (over 3 million shares issued in September 1997) and potential future dilution from convertible debentures.